Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13954850 | 1.00 | SRD5A1 (0.69) | SRD5A1SRD5A2 | |
| SCHEMBL14493964 | 1.00 | SRD5A1 (0.69) | SRD5A1SRD5A2 | |
| SCHEMBL13403482 | 1.00 | SRD5A1 (0.69) | SRD5A1SRD5A2 | |
| SCHEMBL4454380 | 1.00 | SRD5A1 (0.69) | SRD5A1SRD5A2 | |
| SCHEMBL8021083 | 0.87 | SRD5A1 (0.72) | SRD5A1SRD5A2 | |
| SCHEMBL9349878 | 0.87 | SRD5A1 (0.72) | SRD5A1SRD5A2 | |
| SCHEMBL13604091 | 0.87 | SRD5A1 (0.72) | SRD5A1SRD5A2 | |
| SCHEMBL2376048 | 0.87 | SRD5A1 (0.72) | SRD5A1SRD5A2 | |
| SCHEMBL9571051 | 0.87 | SRD5A1 (0.72) | SRD5A1SRD5A2 | |
| SCHEMBL4187752 | 0.87 | SRD5A1 (0.72) | SRD5A1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4377584-A | 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors | MERCK & CO., INC. (US) | 1983-03-22 | — | — | US | claimed |
| EP-1960417-B1 | POLYMORPHS OF ANDROGEN RECEPTOR MODULATOR - (N-3H-IMIDAZO [4 , 5-B] PYRIDIN-2-YL-METHYL) -2-FLUORO-4-METHYL-3-OXO-4-AZA-ANDROST- 1-EN-17 . BETA . -CARBOXAMIDE | MERCK SHARP & DOHME (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20090048283-A1 | Salt of an androgen receptor modulator | MERCK SHARP & DOHME CORP. | 2009-02-19 | — | — | US | disclosed |
| EP-1960417-A1 | POLYMORPHS OF ANDROGEN RECEPTOR MODULATOR - (N-3H-IMIDAZO [4 , 5-B] PYRIDIN-2-YL-METHYL) -2-FLUORO-4-METHYL-3-OXO-4-AZA-ANDROST- 1-EN-17 . BETA . -CARBOXAMIDE | Merck & Co., Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| US-7365202-B2 | Polymorphs of an androgen receptor modulator | MERCK & CO., INC. (US) | 2008-04-29 | — | — | US | disclosed |
| WO-2007067490-A1 | POLYMORPHS OF ANDROGEN RECEPTOR MODULATOR - (N-3H-IMIDAZO [4 , 5-B] PYRIDIN-2-YL-METHYL) -2-FLUORO-4-METHYL-3-OXO-4-AZA-ANDROST- l-EN-17 . BETA . -CARBOXAMIDE | MERCK & CO., INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| US-20070129548-A1 | Polymorphs of an androgen receptor modulator | MERCK SHARP & DOHME CORP. | 2007-06-07 | — | — | US | disclosed |
| US-6432971-B2 | Method of prevention of prostatic carcinoma with 17β-N-monosubstituted-carbamoyl-4-aza-5α-androst-1-en-3-ones | MERCK & CO., INC. | 2002-08-13 | — | — | US | disclosed |
| US-20010049376-A1 | Method of prevention of prostatic carcinoma with 17beta-N-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | MERCK & CO., INC. | 2001-12-06 | — | — | US | disclosed |
| US-6268376-B1 | Method of prevention of prostatic carcinoma with 17β-N-monosubstituted-carbamoyl-4-aza-5α-androst-1-en-3-ones | MERCK & CO., INC. | 2001-07-31 | — | — | US | disclosed |
| WO-1994014452-A1 | METHOD OF TREATMENT OF CHRONIC PROSTATITIS WITH 17β-N-MONOSUBSTITUTED-CARBAMOYL-4-AZA-5α-ANDROST-1-EN-3-ONES | MERCK & CO., INC. (US) | 1994-07-07 | — | — | WO | disclosed |
| US-5302621-A | Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use | SANKYO COMPANY, LIMITED (JP) | 1994-04-12 | — | — | US | disclosed |
| EP-0576603-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC HYPERPLASIA, CONTAINING A 5 ALPHA-REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO. INC. (US) | 1994-01-05 | — | — | EP | disclosed |
| EP-0547691-A1 | The use of 17B-N-mono-substituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones for the preparation of a medicament for the prevention of prostatic carcinoma | MERCK & CO. INC. (US) | 1993-06-23 | — | — | EP | disclosed |
| EP-0547687-A1 | 17B-N-Substituted adamantyl/norbonanyl carbamoyl-4-aza-5a-and-rost-1-en-3-ones and androstan-3 ones | MERCK & CO. INC. (US) | 1993-06-23 | — | — | EP | disclosed |
| EP-0484094-A2 | Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use | Sankyo Company Limited (JP) | 1992-05-06 | — | — | EP | disclosed |
| EP-0004949-B1 | 4-AZA-17-SUBSTITUTED-5-ALPHA-ANDROSTAN-3-ONE, THEIR A AND D HOMO ANALOGS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK & CO. INC. (US) | 1983-09-21 | — | — | EP | disclosed |
| US-4377584-A | 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors | MERCK & CO., INC. (US) | 1983-03-22 | — | — | US | disclosed |
| US-4220775-A | Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors | MERCK & CO., INC. (US) | 1980-09-02 | — | — | US | disclosed |
| EP-0004949-A1 | 4-Aza-17-substituted-5-alpha-androstan-3-one, their A and D homo analogs, process for their preparation and pharmaceutical compositions containing them | MERCK & CO. INC. (US) | 1979-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049376-A1 | Method of prevention of prostatic carcinoma with 17beta-N-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | NR5A1, CYP17A1, HSD17B7 | SRD5A1 8/4885SRD5A2 11/4885 |
| US-20070129548-A1 | Polymorphs of an androgen receptor modulator | SHBG, AR, BRCA1 | SRD5A1 28/4885SRD5A2 36/4885 |
| US-20090048283-A1 | Salt of an androgen receptor modulator | AR, SHBG, FSHR | SRD5A1 29/4885SRD5A2 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.